CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 6,243	$ 3,006
Prepaid expenses and other current assets	382	392
Total current assets	6,625	3,398
Property and equipment, net	142	162
Operating lease right-of-use asset	992	1,052
Other assets	871	948
Total assets	8,630	5,560
Current liabilities:
Accounts payable	1,481	942
Accrued clinical trials expenses	1,173	1,426
Accrued compensation	1,832	2,872
Other accrued expenses	2,183	1,657
Total current liabilities	6,669	6,897
Convertible notes at fair value, including related party amount of $1,542 and $34,600 at March 31, 2026 and December 2025, respectively	1,542	34,600
Operating lease liability	825	893
Derivative liability		14,879
Warrant liabilities	16,308	3,276
Contingent consideration liability	38	42
Total liabilities	25,382	60,587
Commitments and contingencies (Note 7)
Stockholders' Deficit:
Class A common stock, $0.0001 par value; 1,040,000,000 and 500,000,000 shares authorized at March 31, 2026 and December 31, 2025, and 25,303,058 and 12,105,902 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively	10	9
Additional paid-in capital	465,850	415,783
Accumulated deficit	(482,612)	(470,819)
Total stockholders' deficit	(16,752)	(55,027)
Total liabilities and stockholders' deficit	$ 8,630	$ 5,560